Advertisement

International Journal of Clinical Pharmacy

, Volume 36, Issue 4, pp 821–826 | Cite as

Effectiveness of a pilot intervention to reduce abciximab-related bleeding in patients with acute coronary syndromes

  • Ana de Lorenzo-PintoEmail author
  • Héctor Bueno
  • Ana Herranz-Alonso
  • Jaime Elizaga-Corrales
  • Cristina Pérez-Sanz
  • Begoña Cuéllar-Basterrechea
  • Francisco Fernández-Avilés
  • María Sanjurjo-Sáez
Research Article

Abstract

Background and objective Reducing bleeding events is a priority in patients diagnosed with acute coronary syndromes (ACS). The effectiveness of optimization measures for reducing abciximab-related bleeding was evaluated through the implementation of a pilot program developed by the Pharmacy and the Cardiology Departments at a tertiary-care hospital. Main outcome measure Percentage of bleeding events. Results Intervention was effective in reducing the incidence of the three factors associated with an increased risk of bleeding between the pre-intervention phase (n = 86) and the post-intervention phase (n = 73): unknown body weight (24.4 vs. 1.4 %, p = 0.0001), overdosing (31.4 vs. 0 %, p < 0.0001) and combination with bivalirudin (12.8 vs. 1.4 %, p = 0.016). Bleeding events associated with these factors were numerically reduced in all three cases but these differences were not statistically significant between both periods. Conclusion The implementation of a multidisciplinary prevention program can reduce situations associated with an increased risk of bleeding in patients treated with abciximab. Larger scale trials are needed to confirm whether such programs can also reduce the incidence of bleeding at a statistically significant level.

Keywords

Abciximab Acute coronary syndrome Bleeding Cardiology Haemorrhage 

Notes

Acknowledgments

This study is a collaborative effort of the staff working at the coronary care unit (especially to Antonia de Prado), hemodynamic laboratory (Marina), Pharmacy Department, Jose Mª Bellón, Archives Department and Ana Luna.

Funding

This project was funded by a Grant of the Ministerio de Salud, Política Social e Igualdad (SAS/2377/2010, Project Code: EC10-028).

Conflict of interest

Héctor Bueno has received advisory/consulting fees from AstraZeneca, Bayer, Daichii-Sankyo, Eli-Lilly, Novartis, Roche, and research grants from AstraZeneca. All other authors have nothing to disclose.

References

  1. 1.
    Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774–82.PubMedCrossRefGoogle Scholar
  2. 2.
    Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, et al. Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (GRACE). Eur Heart J. 2003;24:1815–23.PubMedCrossRefGoogle Scholar
  3. 3.
    Rao SV, Eikelboom JW, Granger CB, Harrington RA, Califf RM, Bassand JP. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1193–204.PubMedCrossRefGoogle Scholar
  4. 4.
    ISMP’s List of High-Alert Medications [Internet]. [cited 2011 September 3]. http://www.ismp.org/tools/highalertmedications.pdf.
  5. 5.
    Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999–3054.PubMedCrossRefGoogle Scholar
  6. 6.
    Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123(18):e426–579.PubMedCrossRefGoogle Scholar
  7. 7.
    National Patient Safety Agency Alert (2010) Rapid response report: NPSA/2010/RRR014: reducing treatment dose errors with low molecular weight heparins. [cited: 2010 December 30]. http://www.nrls.npsa.nhs.uk/resources/?EntryId45=75208.
  8. 8.
    Hilmer SN, Rangiah C, Bajorek BV, Shenfield GM. Failure to weigh patients in hospital: a medication safety risk. Intern Med J. 2007;37:647–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Izawa S, Enoki H, Hirakawa Y, Masuda Y, Iwata M, Hasegawa J, et al. Lack of body weight measurement is associated with mortality and hospitalization in community-dwelling frail elderly. Clin Nutr. 2007;26:764–70.PubMedCrossRefGoogle Scholar
  10. 10.
    De Lorenzo Pinto A, García DL. Weight does matter. Med Clin (Barc). 2011;137(6):259–61.CrossRefGoogle Scholar
  11. 11.
    Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203–16.PubMedCrossRefGoogle Scholar
  12. 12.
    Mehran R, Lansky AJ, Witzenbichler B. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149–59.PubMedCrossRefGoogle Scholar
  13. 13.
    Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium (BARC). Circulation. 2011;123:2736–47.PubMedCrossRefGoogle Scholar
  14. 14.
    Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, et al. Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (GRACE). Eur Heart J. 2003;24:1815–23.PubMedCrossRefGoogle Scholar
  15. 15.
    Berkowitz SD, Granger CB, Pieper KS, Lee KL, Gore JM, Simoons M, et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO) I investigators. Circulation. 1997;95:2508–16.PubMedCrossRefGoogle Scholar
  16. 16.
    Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.PubMedCrossRefGoogle Scholar
  17. 17.
    Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593–601.PubMedCrossRefGoogle Scholar
  18. 18.
    Corbo J, Canter M, Grinberg D, Bijur P. Who should be estimating a patient’s weight in the emergency department? Acad Emerg Med. 2005;12(3):262–6.PubMedCrossRefGoogle Scholar
  19. 19.
    del García MMR, Morales Laborías ME, Fernández López I, Rodríguez Delgado E, Díaz Castellanos MA. Subjective estimation of patient weight and height in the ICU. Non-advisable measures. Med Intensiva. 2013;37:50–2.CrossRefGoogle Scholar
  20. 20.
    The Clinician’s Ultimate Reference. [cited 2011 Sep 5]. http://www.globalrph.com/abciximab_dilution.htm.
  21. 21.
  22. 22.
    Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294(24):3108–16.PubMedCrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014

Authors and Affiliations

  • Ana de Lorenzo-Pinto
    • 1
    Email author
  • Héctor Bueno
    • 2
  • Ana Herranz-Alonso
    • 1
  • Jaime Elizaga-Corrales
    • 2
  • Cristina Pérez-Sanz
    • 1
  • Begoña Cuéllar-Basterrechea
    • 1
  • Francisco Fernández-Avilés
    • 2
  • María Sanjurjo-Sáez
    • 1
  1. 1.Pharmacy Department, Instituto de Investigación Sanitaria Gregorio MarañónHospital General Universitario Gregorio MarañónMadridSpain
  2. 2.Cardiology Department, Instituto de Investigación Sanitaria Gregorio MarañónHospital General Universitario Gregorio MarañónMadridSpain

Personalised recommendations